Pfizer to launch OTC antihistamine/vasoconstrictor product in coming months.
This article was originally published in The Tan Sheet
Executive Summary
PFIZER ADDING OTC ANTIHISTAMINE/VASOCONSTRICTOR PRODUCT to its consumer eyecare offering. The product, which will be marketed by Pfizer's Consumer Health Care Group under a 1994 licensing agreement with Akorn, Inc., is expected to be launched in the coming months. FDA approved Akorn's Rx-to-OTC switch NDA for the pheniramine maleate .3%/naphazoline HCl 0.25% eye drops under the name OcuHist on Jan. 31.